Celltrion to directly sell Remsima SC, secure own direct global distribution network
IndustryJan 6, 2019
South Korean biosimilar firm Celltrion will establish a direct sales network for its drugs worldwide, and specifically Remsima SC -- a subcutaneous version of Remsima -- in an effort to secure price competitiveness and lead the global biosimilar market, its chief said in a New Year’s press conference last week.The firm is also working toward opening a joint company in China within the first half of the year as part of the plan, said Celltrion’s founder and Chairman Seo Jung-jin. Apart from strat